SCHEDULE 13G: Tang Capital Group Discloses 9.99% Stake in ITeos Therapeutics
Beneficial Ownership Report
Tang Capital Management, Kevin Tang, and affiliated entities have jointly reported beneficial ownership of 9.99% of ITeos Therapeutics, Inc.'s common stock.
Summary
- Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, and Tang Capital Partners International, LP, along with Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc., have filed a Schedule 13G.
- The reporting group collectively beneficially owns 3,826,692 shares of ITeos Therapeutics, Inc. Common Stock.
- This ownership represents 9.99% of the outstanding Common Stock, calculated based on 38,273,795 shares outstanding as of April 22, 2025, as reported in the Issuer's Form 10-Q.
- All reported shares are held with shared voting and shared dispositive power among the primary reporting entities.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, providing no explicit positive or negative sentiment regarding the company's performance or outlook.
Positives
- A significant institutional investor group, Tang Capital, has disclosed a nearly 10% stake, indicating substantial investment interest in ITeos Therapeutics.
Future Outlook
The document is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This filing is a standard disclosure of beneficial ownership by an institutional investor group in a publicly traded biotechnology company, ITeos Therapeutics, Inc. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially signaling investor confidence in ITeos Therapeutics.
Key Dates
| Date | Description |
|---|---|
| 2025-04-22 | Date as of which 38,273,795 shares of Common Stock were outstanding, as reported in Issuer's Form 10-Q. |
| 2025-04-28 | Date Issuer's Quarterly Report on Form 10-Q was filed with the SEC. |
| 2025-05-13 | Date of event which requires filing of this statement (beneficial ownership threshold crossed/met). |
| 2025-05-15 | Date of filing of this Schedule 13G statement. |
Keywords
ITeos Therapeutics, Tang Capital Management, Kevin Tang, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, SEC Filing, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.